Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection

• Status: Completed
• Trial end date: 2013-04-01

Summary

To test the efficacy of 14 day levofloxacin and bismuth-containing second-line therapy for resistant Helicobacter pylori infection, to compare with the classical quadruple therapy.

• Phase: Phase 4

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Amoxicillin; Bismuth; Bismuth subsalicylate; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Tetracycline